🔬 Does a Screening Trial for Spinal Cord Stimulation in Patients with Chronic Pain of Neuropathic Origin Have Clinical Utility and Cost-Effectiveness?
🌟 1.0 #CME
📄 Authors: Sam ElDabe, Rui V Duarte, Ashish Gulve, Simon Thomson, Ganesan Baranidharan, Rachel Houten, Susan Jowett, Harbinder Sandhu, Raymond Chadwick, Morag Brookes, Anu Kansal, Jenny Earle, Jill Bell, Jennifer Robinson, Sarah Walker, Shelley Rhodes, Rod S Taylor
This randomized controlled trial, conducted across three UK centers, compared SCS screening trial strategy (TG) versus no trial screening strategy (NTG). The primary outcome measured was the numerical rating scale (NRS) pain at 6 months.
Key Findings:
➔No significant difference in pain reduction between TG and NTG groups.
➔SCS screening trials showed high sensitivity but low specificity.
➔The cost-effectiveness analysis revealed an incremental cost-effectiveness ratio of £78,895 per additional quality-adjusted life-year gained.
https://lnkd.in/gZQqVeDu
#MedicalResearch #ChronicPain #SpinalCordStimulation #ClinicalTrial #CostEffectiveness #PhysicianInsights #MedicalPractice #DoctorsUpdate